GlobeNewswire by notified

Impulse Dynamics Receives Full-Body MRI-Conditional Approval for Optimizer Smart Mini System

Share

Reflecting Company Commitment to Innovation in Support of Patient Need

MARLTON, N.J., Oct. 30, 2023 (GLOBE NEWSWIRE) -- Impulse Dynamics, a global medical device company dedicated to improving the lives of people with heart failure (HF), announced today it has received whole-body MRI-conditional approval for the Optimizer® Smart Mini system from the United States Food and Drug Administration (FDA). The Optimizer Smart Mini system delivers the company’s proprietary CCM® therapy. This conditional approval expands the product labeling to allow for full-body magnetic resonance (MRI) diagnostic imaging with 1.5 and 3.0 Tesla (T) scanners. The approval for use with full-body MRI covers new patients adopting CCM therapy as well as existing Optimizer Smart Mini users.

“We are pleased to receive approval for this important labeling change reflecting a necessary option for heart failure patients who likely receive multiple surgeries and benefit from the use of MRI imaging in the course of their treatment,” said Jason Spees, CEO of Impulse Dynamics. “This furthers our commitment to supporting the heart failure patients who benefit from important and life-changing CCM therapy with the Optimizer Smart Mini system.”

“Full body MRI capability is part of our promise to deliver an ongoing pace of innovation,” said David Prutchi, Ph.D., Chief Technology Officer, Impulse Dynamics. “This advance will ensure that patients who can benefit from our CCM therapy are able to pursue the option without limiting important future diagnostic options.”

The Optimizer Smart Mini delivers CCM therapy to the heart. CCM therapy delivers precisely timed electrical pulses to the heart that are intended to improve the heart’s ability to contract, allowing more oxygen-rich blood to be pushed out through the body.1 CCM therapy is indicated to improve 6-minute hall walk, quality of life, and functional status of NYHA (New York Heart Association) Class III heart failure patients who remain symptomatic despite guideline-directed medical therapy, are not indicated for CRT (cardiac resynchronization therapy), and have a left ventricular ejection fraction ranging from 25 to 45 percent.

The Optimizer Smart Mini incorporates a rechargeable battery with 20-year battery life, offering HF diagnostic monitoring that provides important clinical insights to providers to assist in managing their patients with heart failure. This latest generation also offers internal technology with improved programming and a smaller size designed to make the implant procedure faster and easier for patients and physicians.


Reference

1    Kuschyk J, Falk P, Demming T, et al. Long‐term clinical experience with cardiac contractility modulation therapy delivered by the optimizer smart system. European Journal of Heart Failure. 2021;23(7):1160-1169. doi:10.1002/ejhf.2202 

 # # #

About Impulse Dynamics
Impulse Dynamics is dedicated to advancing the treatment of heart failure for patients and the healthcare providers who care for them. The company pioneered its proprietary CCM therapy, which uses the Optimizer technology platform to improve quality of life in heart failure patients. CCM therapy is delivered through the Optimizer system, which includes an IPG implanted in a minimally invasive procedure and approved for commercial use in the United States and 44 countries worldwide. More than 9,000 patients have received the therapy as part of clinical trials and real-world use, where it is proven to be safe and effective for heart failure patients with debilitating symptoms who otherwise have few effective options available to them. To learn more, visit www.ImpulseDynamics.com or follow the company on LinkedIn, Twitter, and Facebook.

Forward-Looking Statements
This press release contains forward-looking statements. All statements other than statements of historical facts contained in this press release are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as ‘‘may,’’ ‘‘will,’’ ‘‘should,’’ ‘‘expect,’’ ‘‘plan,’’ ‘‘anticipate,’’ ‘‘could,’’ ‘‘intend,’’ ‘‘target,’’ ‘‘project,’’ ‘‘contemplate,’’ ‘‘believe,’’ ‘‘estimate,’’ ‘‘predict,’’ ‘‘potential’’ or ‘‘continue’’ or the negative of these terms or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements include, but are not limited to, statements concerning potential benefits of CCM therapy. These forward-looking statements are based on management’s current expectations and involve known and unknown risks and uncertainties that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Other important factors that could cause actual results, performance or achievements to differ materially from those contemplated in this press release include, without limitation: the company’s future research and development costs, capital requirements and the company’s needs for additional financing; commercial success and market acceptance of CCM therapy; the company’s ability to achieve and maintain adequate levels of coverage or reimbursement for Optimizer systems or any future products the company may seek to commercialize; competitive companies and technologies in the industry; the company’s ability to expand its indications and develop and commercialize additional products and enhancements to its current products; the company’s business model and strategic plans for its products, technologies and business, including its implementation thereof; the company’s ability to expand, manage and maintain its direct sales and marketing organization; the company’s ability to commercialize or obtain regulatory approvals for CCM therapy and its products, or the effect of delays in commercializing or obtaining regulatory approvals; FDA or other U.S. or foreign regulatory actions affecting us or the healthcare industry generally, including healthcare reform measures in the United States and international markets; the timing or likelihood of regulatory filings and approvals; and the company’s ability to establish and maintain intellectual property protection for CCM therapy and products or avoid claims of infringement. The company does not undertake any obligation to update forward-looking statements and expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein. These forward-looking statements should not be relied upon as representing the company’s views as of any date subsequent to the date of this press release.

ID-A358-US  

Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Landsbankinn hf.: Offering of subordinated bonds in ISK27.2.2024 11:27:25 CET | Press release

Reference is made to an announcement made by Landsbankinn on 16 February 2024 regarding a proposed sale via closed auction of Tier 2 subordinated bonds in ISK. Landsbankinn will offer two series of Tier 2 subordinated bonds in ISK for sale, an inflation-linked series and a non-indexed series. The inflation-linked series will have a coupon of 5.70% and will be sold at a predetermined price of 100 which equals a yield of 5.70%. The series pays an annual coupon with one payment of principal at maturity. The non-indexed series will have coupon of 9.60% and will be sold at a predetermined price of 100 which equals a yield of 9.60%. The series pays an annual coupon with one payment of principal at maturity. Minimum size of issued series is ISK 3 bn. Landsbankinn reserves the right to accept any bid, either partially or in full, or to reject all bids. Final maturity on both series will be 7 March 2035 and a call date on 7 March 2030 and on every interest payment date thereafter (11NC6). The s

AVENIR LNG LIMITED REPORTS BUSINESS UPDATE PRESENTATION27.2.2024 11:06:52 CET | Press release

February 27,2024, Avenir LNG Limited (NOTC: AVENIR) is pleased to present its first management business update presentation to its shareholders. The company aims to provide further updates on regular basis to shareholders with the intent to provide a better insight in the group strategy and commercial outlook. The company is operating in an environment with strong fundamental drivers, driven by regulations, emissions reductions, and a 10x forecasted growth in marine LNG volumes. Avenir is a leader and a pioneer in the small-scale LNG and LNG bunkering market, having developed a strong track record in wholesale trading, LNG supply, and ship-to-ship bunkering. With a small and fragmented number of participants in the market, Avenir, as one of the largest owners of LNG bunker vessels, is well positioned to capitalise on the growth in the LNG marine fuels sector. As of today, the Avenir fleet has strong utilisation with 4 of its 5 vessels serving short-medium term charters for 3rd party bu

Huhtamaki's 2023 Annual Report published27.2.2024 11:00:00 CET | Press release

HUHTAMÄKI OYJ STOCK EXCHANGE RELEASE 27.2.2024 AT 12:00 EET Huhtamaki's 2023 Annual Report published The Huhtamaki Annual Report 2023 has been published on the company's website at www.huhtamaki.com/investors. It is comprised of four sections, with a Company overview, financials, governance (Corporate Governance Statement and Remuneration Report) and sustainability. The report is available in Finnish and English apart from the Sustainability Report, which is available only in English. The financial statements are published in accordance with the European Single Electronic Format (ESEF) reporting requirements. The audit firm KPMG Oy Ab has provided an independent auditor’s reasonable assurance report on Huhtamaki’s ESEF Financial Statements in accordance with ISAE 3000 (Revised). The Annual Report is attached to this release as a PDF file and the financial statements as an XHTML file. For further information, please contact: Kristian Tammela, Vice President, Investor Relations, tel. +35

Indkaldelse til ordinær generalforsamling i Fynske Bank A/S27.2.2024 11:00:00 CET | pressemeddelelse

Selskabsmeddelelse nr. 2024/04 Fynske Bank A/S afholder ordinær generalforsamling torsdag den 21. marts 2024 kl. 16.30 på Hotel Christiansminde, Christiansmindevej 16, 5700 Svendborg. Fuldstændig dagsorden i henhold til vedtægternes § 7: Bestyrelsens beretning om bankens virksomhed i det forløbne årFremlæggelse af revideret årsrapport til godkendelseBeslutning om anvendelse af overskud eller dækning af tab i henhold til den godkendte årsrapportPræsentation af og vejledende afstemning om vederlagsrapportenForslag fra repræsentantskab, bestyrelse og aktionærer Der er ingen indkomne forslag Valg af medlemmer til repræsentantskabet. Følgende opstiller til valget: Senior projektleder Hans C. Sørensen, Svendborg Markedsdirektør Jørgen Ø. Mortensen, Nyborg Adm. direktør og partner Kasper Kjærsgaard Jensen, Odense Overlæge Kirsten Søgaard, Thurø Partner, Headhunter Lars B. Nielsen, Aarhus Autoforhandler Lars Hindsgaul Madsen, Assens Salgschef Marcel Mensel-Legald, Kolding Adm. direktør Martin

Referat af ekstraordinær generalforsamling i Scape Technologies A/S27.2.2024 10:52:42 CET | pressemeddelelse

Nasdaq First North Growth Market Denmark Selskabsmeddelelse nr. 63/2024 Odense, 27. februar 2024 Referat af ekstraordinær generalforsamling i Scape Technologies A/S Tirsdag den 27. februar 2024 kl. 9.00 blev der afholdt ekstraordinær generalforsamling i Scape Technologies A/S på selskabets adresse Østerbro 5C, 5000 Odense C. Dagsorden for den ekstraordinære generalforsamling: 1. Valg af dirigent 2. Bemyndigelse til at gennemføre kapitalforhøjelser Ad dagsordenens punkt 1. Bestyrelsen stillede forslag om valg af Søren Bøving-Anderen som dirigent for generalforsamlingen. Forslaget blev enstemmig vedtaget. Ingen af aktionærerne havde indvendinger mod generalforsamlingens lovlighed, og dirigenten konstaterede, at generalforsamlingen var rettidigt indkaldt jvf selskabets vedtægter og dermed var beslutningsdygtig i relation til dagsordenens punkter. Ad dagsordenens punkt 2. Med henblik på at sikre fleksibilitet til kapitalisering af selskabet, blev der stillet forslag om, at bestyrelsens eks

HiddenA line styled icon from Orion Icon Library.Eye